Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The study is a non-randomized clinical treatment trial focusing on R-5780 in patients diagnosed with Basal-cell Carcinoma, Melanoma (cutaneous), or Squamous Cell Carcinomas. These patients are refractory to Anti-PD-1 antibodies or Anti-PD-L1 antibodies therapy, according to RECIST v1.1 criteria. This means that the subjects have experienced disease progression after undergoing at least two complete cycles of [immune checkpoint inhibitors (ICI)](…